Seeking Alpha

More on Baxter (BAX) Q1: net profit -11% to $552M, dragged down by charges related to its...

More on Baxter (BAX) Q1: net profit -11% to $552M, dragged down by charges related to its purchase of Gambrro, while last year's figures included a tax benefit. Medical-products sales -0.4% to $1.92B, BioScience revenue +4.7% to $1.53B. Expects sales growth of 4% in Q2 and 10% for FY; forecasts EPS of Q2 EPS of $1.12-1.14 vs consensus of $1.14 and 2014 EPS of $4.60-4.70 vs 4.66. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|